Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases characterized by ineffective hematopoiesis leading to cytopenia(s), morphological dysplasia, and an increased risk of development of acute myeloid leukemia (AML).
Other cytogenetic abnormalities detected in the setting of refractory cytopenia, even in the absence of dysplasia, are considered as presumptive evidence of MDS, and such cases are classified as "MDS, unclassifiable." 2 Karyotypes have been stratified into 5 risk categories in MDS patients: very good, good, intermediate, poor, and very poor according to the Revised International Prognosis Scoring System (IPSS) 4, 5 ( Table 1 ). In this risk categorization scheme, of the commonly detected chromosomal abnormalities, -Y is considered as very good, del(5q) and del(20q) as good, del(7q) as intermediate, -7 and 3 abnormalities as poor, and a complex karyotype with >3 abnormalities as very poor.
Therapy-related MDS (t-MDS) is a late complication of chemotherapy and/or radiation therapy, and these patients usually have a poor outcome. 1, 6 Cytogenetic abnormalities can be detected in around 90% of these patients, and complex karyotype in ~50% of patients. A newly emerged CCA in a patient with cytopenia(s) and a prior history of cytotoxic therapy is highly suspicious for the development of t-MDS. Recent studies, however, have shown that CCA can be occasionally detected in the BM of patients who do not have BM disease; most of these CCAs are not associated with underlying MDS.
| CC AUS COULD B E AG E-REL ATED
Loss of the Y chromosome (−Y) is a relatively common finding in the BM of elderly men and is often considered as a result of aging or a benign finding. Loss of the X chromosome (−X) as a sole abnormality has been reported in phytohemagglutinin (PHA)-stimulated PB T lymphocytes, [9] [10] [11] and a relationship between -X and aging has been shown. may not be pathognomonic for a neoplastic hematopoietic neoplasm when it presents as a sole abnormality, instead, it could be an agerelated change similar to −Y and −X. with −Y, +8, −7/del(7q), and del(20q) being the most common.
| CC AUS EMERG ING DURING T YROS INE K INA S E INHIB ITOR THER APY
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Interestingly, most CCAs in Ph− cells are transient, lasting only for a limited time interval, and are of undetermined significance [20] [21] [22] ; less than 10% of patients may develop a secondary MDS/AML, and the latter group is composed mainly of patients with monosomy 7 or a complex karyotype. 18, 20, 22, 23 Del(5q), a cytogenetic abnormality highly associated with myeloid neoplasms, also can be observed occasionally in Ph-cells. In our previous study, 24 4 patients were found to have del(5q) in their BM during TKI therapy and, with 8-to 59-month follow-up, none of these patients developed secondary myeloid neoplasms. 24 The overall prognosis and responses to TKI for CML patients who developed CCA in Ph-cells are similar to those without CCA, and the prognosis is primarily dictated by CML response to imatinib and is not affected by CCA. 18, 19 Isolated CCA detected in Ph-cells in the absence of morphologic evidence of MDS does not require a change in therapy. 18 In a recent study by Issa et al, 22 it is noteworthy that CCA in Ph-cells was not commonly associated with the development of secondary myeloid neoplasms, but these patients showed inferior eventfree survival, transformation-free survival, and overall survival. 
| CC AUS EMERG ING AF TER C Y TOTOXI C THER APIE S
Cytotoxic therapies mainly include chemotherapy and radiation therapy. Chemotherapy regimens commonly include alkylating agents, topoisomerase II inhibitors, and other agents (antimetabolites and antitubulin agents). Among forms of radiation therapy, external-beam radiation involving large active hematopoietic BM area can lead to t-MDS/ AML; whereas, brachytherapy or radioisotopes alone are not directly associated with t-MDS/AML. 25 Other therapies, including monoclonal antibody (rituximab), immune therapies (Bacillus Calmette-Guerin, interferon, and interleukin-2), or hormonal therapy (tamoxifen), alone are not considered as cytotoxic therapies, but their synergetic effect in the pathogenesis of t-MDS/AML has been suggested by others. rearrangement. About 5%-10% of patients may develop CCA after cytotoxic therapies, 27, 28 and about 3%-5% may eventually develop secondary MDS or AML. 26, 27 There is substantial overlap between CCA in patients with MDS and CCA in patients as CCAUS; however, some features of CCA can help to distinguish CCAUS from MDS.
| Clone size
The size of the CCA clone is one of the most important factors to be considered when a CCA is detected in the post cytotoxic therapy setting and the differential diagnosis includes CCAUS vs Several genes have been shown to be involved in the pathogenesis of 5q-syndrome. RPS14 gene, located on 5q33.1, is critical for erythroid development 37, 38 ; a microRNA cluster on chromosome 5q32-33, including miR-143, miR-145, and miR-146a, is important for megakaryocytic differentiation 39 ; EGR1, located on 5q31, plays an important role in hematopoietic stem cell proliferation. 40 Del(5q) is detected in ~ 20% of patients with t-MDS/AML. 41 In an earlier study of 21 patients who acquired isolated del(5q) after cytotoxic therapy, 24 12(57%) patients developed t-MDS or t-AML and 9 patients did not. Interestingly, 4 of 21 patients had deletions that spared both
| Characteristics of CCA
CDRs, and only one of these 4 patients developed t-MDS which showed different BM features from those of typical 5q-syndrome.
These findings suggest that factors other than del(5q) also might play a role in the pathogenesis of t-MDS. 24 Next-generation sequencing (NGS) studies to identify myeloid neoplasms-associated somatic mutations may shed light on the pathogenesis of these cases.
Patients with de novo MDS and isolated del(20q) may be associated with only minimal morphologic dysplasia 42, 43 and often have an indolent clinical course. 42, 44 Del(20q) as a sole abnormality is uncommon in t-MDS/AML. 45, 46 In a study that included 92 patients who acquired del(20q) as the sole abnormality after cytotoxic therapy, only 21 (23%) patients had a diagnosis of t-MDS/AML, 46 had no evidence of t-MDS/AML, and 25 had an inconclusive BM diagnosis with a median follow-up of 23 months. 29 The results of these studies suggest that CCA detected in the BM following cytotoxic therapy, even the cytogenetic abnormalities typically associated with t-MDS/AML, can be CCAUS. Comparison of features between CCAUS and CCA associated with t-MN is summarized in Table 2 . Caution is needed when interpreting CCA in patients with normal BM findings, 47 especially when CCA size is small.
Mutation studies may be helpful in further delineating a benign vs neoplastic process. Close follow-up to monitor the persistence of the clone, clonal expansion, clonal evolution, and emergence of features for t-MDS/AML seems most appropriate.
| CHALLENG E S IN DIS TING UIS HING CC AUS FROM MDS
A diagnosis of MDS requires the presence of cytopenia (1-3 
| PATHOG ENE S IS OF CC AUS
Several hypotheses have been suggested for the pathogenesis of CCAUS. or KIT mutation) is necessary to promote proliferation or survival of the neoplastic clone. 54 We have observed that some patients can harbor an abnormal clone for years without any evidence of a myeloid neoplasm, but MDS/AML develops with the occurrence of clonal evolution or emergence of a new abnormal clone. 30, 53 These studies on CCAUS indicate that some CCA may also require addi- 
| Chromosomal alterations not interfering normal hematopoiesis
| CON CLUS ION
Detection of an abnormal cytogenetic clone in a morphologically normal BM is often not associated with a myeloid neoplasm, especially when the abnormal clone is small and isolated abnormality These patients require close follow-up and surveillance for clonal expansion/evolution or emergent evidence of MDS.
CO N FLI C T O F I NTE R E S T S
The authors report no potential conflict of interests.
O RCI D
G. Tang http://orcid.org/0000-0002-9482-4806
